Form 4: Veracyte CCO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Veracyte's Chief Commercial Officer, John Leite, sold 2,539 shares of common stock for $35 per share under a pre-arranged 10b5-1 trading plan.
Summary
- John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), reported a sale of common stock.
- The transaction involved the disposition of 2,539 shares of common stock.
- The shares were sold at a price of $35 per share.
- The total value of the shares sold was $88,865.
- Following this transaction, John Leite beneficially owns 89,099 shares of Veracyte common stock.
- The sale was executed on October 1, 2025, and was made pursuant to a Rule 10b5-1 plan adopted on June 9, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which suggests personal financial planning rather than a reaction to new, non-public information. The transaction size is also not exceptionally large relative to the insider's remaining holdings.
Negatives
- An insider sale, even if pre-planned, can sometimes be perceived negatively by investors, though the Rule 10b5-1 plan mitigates concerns about opportunistic timing.
Risks
- Insider selling, even under a 10b5-1 plan, could be misinterpreted by the market as a lack of confidence, potentially impacting investor sentiment.
Future Outlook
This Form 4 filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape for Veracyte, Inc. (VCYT).
Stakeholder Impact
- Shareholders: May observe the insider sale, but the 10b5-1 plan context typically mitigates concerns about management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| June 9, 2025 | Date the Rule 10b5-1 plan was adopted by the reporting person. |
| October 1, 2025 | Date of the reported transaction (sale of common stock). |
| October 3, 2025 | Date the Form 4 was signed. |
Keywords
Veracyte, VCYT, John Leite, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.